IRIS
RUZZO, ANNAMARIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 13.297
EU - Europa 7.810
AS - Asia 5.456
SA - Sud America 479
AF - Africa 86
OC - Oceania 46
Continente sconosciuto - Info sul continente non disponibili 17
AN - Antartide 2
Totale 27.193
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 13.160
CN - Cina 2.664
GB - Regno Unito 2.528
SG - Singapore 1.472
UA - Ucraina 1.208
IT - Italia 891
FR - Francia 681
TR - Turchia 520
SE - Svezia 508
RU - Federazione Russa 494
DE - Germania 488
FI - Finlandia 408
BR - Brasile 381
VN - Vietnam 247
IE - Irlanda 239
PL - Polonia 121
HK - Hong Kong 104
IN - India 104
CA - Canada 81
AT - Austria 79
KR - Corea 57
AU - Australia 40
NL - Olanda 40
JP - Giappone 39
MX - Messico 36
BD - Bangladesh 34
AR - Argentina 32
BE - Belgio 29
PK - Pakistan 28
ZA - Sudafrica 28
ES - Italia 24
ID - Indonesia 23
IQ - Iraq 23
EC - Ecuador 22
SA - Arabia Saudita 20
IR - Iran 17
EU - Europa 15
VE - Venezuela 13
JO - Giordania 11
PH - Filippine 11
TN - Tunisia 11
UZ - Uzbekistan 11
EG - Egitto 10
RO - Romania 9
AE - Emirati Arabi Uniti 8
BG - Bulgaria 8
MA - Marocco 8
CL - Cile 7
LT - Lituania 7
TG - Togo 7
AL - Albania 6
NZ - Nuova Zelanda 6
PE - Perù 6
UY - Uruguay 6
CO - Colombia 5
DZ - Algeria 5
KE - Kenya 5
KG - Kirghizistan 5
MD - Moldavia 5
PA - Panama 5
TW - Taiwan 5
AM - Armenia 4
AZ - Azerbaigian 4
CZ - Repubblica Ceca 4
DO - Repubblica Dominicana 4
GR - Grecia 4
IL - Israele 4
LK - Sri Lanka 4
LV - Lettonia 4
MY - Malesia 4
NG - Nigeria 4
OM - Oman 4
PY - Paraguay 4
TH - Thailandia 4
BH - Bahrain 3
BO - Bolivia 3
CH - Svizzera 3
DK - Danimarca 3
GD - Grenada 3
HN - Honduras 3
HR - Croazia 3
LU - Lussemburgo 3
MM - Myanmar 3
NP - Nepal 3
SK - Slovacchia (Repubblica Slovacca) 3
BA - Bosnia-Erzegovina 2
CI - Costa d'Avorio 2
ET - Etiopia 2
GE - Georgia 2
HU - Ungheria 2
JM - Giamaica 2
KZ - Kazakistan 2
LB - Libano 2
MO - Macao, regione amministrativa speciale della Cina 2
SN - Senegal 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AO - Angola 1
AQ - Antartide 1
BN - Brunei Darussalam 1
BY - Bielorussia 1
Totale 27.175
Salva come PNG Salva come JPEG
Città #
Southend 2.274
Fairfield 1.665
Woodbridge 1.291
Ashburn 1.274
Houston 1.164
Jacksonville 963
Singapore 762
Seattle 719
Ann Arbor 679
Cambridge 670
Wilmington 645
Nanjing 607
Chandler 515
San Jose 511
Izmir 400
Beijing 352
Dallas 346
Boardman 244
Dublin 240
Nanchang 215
Helsinki 169
New York 161
Lauterbourg 151
Princeton 144
Los Angeles 141
Bremen 135
Urbino 110
Shenyang 108
Tianjin 102
San Mateo 101
Kunming 98
Hong Kong 97
Düsseldorf 91
Hebei 90
Kraków 90
Ho Chi Minh City 87
Moscow 84
Jiaxing 72
Istanbul 70
Changsha 67
San Diego 67
Vienna 65
Munich 59
Buffalo 57
Shanghai 55
Hangzhou 54
London 50
San Francisco 49
Guangzhou 45
Hanoi 44
Seongnam 44
The Dalles 43
Velikiy Novgorod 42
São Paulo 41
Santa Clara 38
Chicago 36
Toronto 36
Jinan 34
Ancona 30
Rome 30
Falls Church 29
Tokyo 29
Brooklyn 28
Lanzhou 28
Denver 27
Ningbo 27
Frankfurt am Main 26
Nuremberg 25
Orem 25
Changchun 24
Milan 24
Warsaw 24
Strasbourg 23
Zhengzhou 23
Brussels 22
Stockholm 22
Atlanta 20
Dearborn 19
Boston 18
Montreal 18
Poplar 18
Rio de Janeiro 17
Johannesburg 16
Pesaro 16
Phoenix 16
Riyadh 16
Mülheim 15
Redwood City 15
Taizhou 15
Council Bluffs 14
Manchester 14
Acton 13
Amsterdam 13
Chennai 13
Melbourne 13
Paris 13
Quito 13
Rimini 13
Augusta 12
Hefei 12
Totale 19.391
Salva come PNG Salva come JPEG
Nome #
2196 Polymorphisms and miRNAs targeting CLOCK gene affect gender-related survival in metastatic colorectal cancer (mCRC) patients (pts) 347
XRCC1 399GG genotype predicts significantly longer overall survival in resistant lymphoma patients treated with Benda-EAM and ASCT 313
TS, MTHFR AND XRCC1 GENETIC VARIANTS INFLUENCE THE OUTCOME OF MDS PATIENTS IRRESPECTIVELY OF IPSS RISK 308
C-MET gene copy number variation (CNV) analysis by quantitative PCR (qPCR) assay in Caucasian patients with gastric cancer (GC). 299
Genetic markers for toxicity of adjuvant oxaliplatin and fluoropyrimidines in the phase III TOSCA trial in high-risk colon cancer patients 293
The Mutational Status Of Genes Involved In DNA Repair and Folate Pathway Predicts Overall Survival Of Patients With Low-Risk, Untreated Myelodysplastic Syndrome 286
Endogastric capsule for E-cadherin gene (CDH1) promoter hypermethylation assessment in DNA from gastric juice of diffuse gastric cancer patients. 265
Dihydropyrimidine dehydrogenase (DPYD) gene polymorphisms profiling in colon cancer patients treated with adjuvant chemotherapy in the randomized phase III TOSCA trial 260
Glucose metabolism enzymes gene expression analysis and selective metabolic advantage in the progression of colorectal cancer (CRC) 259
VEGF gene polymorphisms in the prediction of benefit from first-line FOLFIRI plus bevacizumab (BV) in metastatic colorectal cancer (mCRC) patients (pts) 257
Clinical impact of the HGF/MET pathway activation in patients with advanced gastric cancer treated with palliative chemotherapy 256
Effect of polymorphisms and miRNAs targeting CLOCK gene on gender-related survival in metastatic colorectal cancer (mCRC) patients (pts). 250
BRAF V600E mutation and Amphiregulin (AR) immunohistochemical expression in the prediction of benefit from cetuximab plus irinotecan in KRAS wild-type metastatic colorectal cancer (mCRC) patients 247
Targeting wild-type KRAS-amplified gastroesophageal cancer through combined MEK and SHP2 inhibition. 245
Genetic modulation of the Interleukin 6 (IL-6) system in patients with advanced gastric cancer: a background for an alternative target therapy 239
Genetic modulation of the Let-7 microRNA binding to KRAS 3'-untranslated region and survival of metastatic colorectal cancer patients treated with salvage cetuximab-irinotecan 239
VEGF GENE POLYMORPHISMS IN THE PREDICTION OF BENEFIT FROM FIRST-LINE FOLFIRI PLUS BEVACIZUMAB (BV) IN METASTATIC COLORECTAL CANCER (MCRC) PATIENTS (PTS) 235
Evaluation of MET using FISH, IHC, or mass spectrometry as a prognostic biomarker in patients with gastroesophageal cancer 232
Assignment of the hexokinase type 3 gene (HK3) to human chromosome band 5q35.3 by somatic cell hybrids and in situ hybridization 226
A Novel Homozygous Variant in the Fork-Head-Associated Domain of Polynucleotide Kinase Phosphatase in a Patient Affected by Late-Onset Ataxia With Oculomotor Apraxia Type 4 224
MET as a prognostic biomarker of survival in a large cohort of patients with gastroesophageal cancer (GEC) 222
Association of Thymidylate Synthase Polymorphisms with Gastric Cancer Susceptibility 221
THE EXPRESSION OF THE KRAS mRNA ISOFORMS 4A AND 4B IN PLASMA: A COMPARISON BETWEEN LUNG ADENOCARCINOMA PATIENTS AND HEALTHY DONORS THROUGH LIQUID BIOPSY 220
An erythroid-specific exon is present in the human hexokinase gene 219
Gender effects of single nucleotide polymorphisms and miRNAs targeting clock-genes in metastatic colorectal cancer patients (mCRC) 218
Author Correction: Targeting wild-type KRAS-amplified gastroesophageal cancer through combined MEK and SHP2 inhibition 218
Glucose metabolism enzymes gene expression analysis and selective metabolism advantage in the clinical progression of colorectal cancer (CRC) 216
BRAF V600E MUTATION AND AMPHIREGULIN (AR) IMMUNOHISTOCHEMICAL EXPRESSION IN THE PREDICTION OF BENEFIT FROM CETUXIMAB PLUS IRINOTECAN IN KRAS WILD-TYPE METASTATIC COLORECTAL CANCER (mCRC) PATIENTS 215
Structure of the human hexokinase type I gene and nucleotide sequence of the 5' flanking region 213
PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer. 213
Cetuximab plus irinotecan after irinotecan failure in elderly metastatic colorectal cancer patients: clinical outcome according to KRAS and BRAF mutational status. 213
MTHFR, TS and XRCC1 genetic variants may affect survival in patients with myelodysplastic syndromes treated with supportive care or azacitidine 212
Prospective study of EGFR intron 1 (CA)n repeats variants as predictors of benefit from cetuximab and irinotecan in chemo-refractory metastatic colorectal cancer (mCRC) patients 212
High resolution melting (HRM) analysis for the detection of ER22/23EK, BclI, and N363S polymorphisms of the glucocorticoid receptor gene. 211
Association of CDH1 haplotypes with susceptibility to sporadic diffuse gastric cancer 210
Glycolysis gene expression analysis and selective metabolic advantage in the clinical progression of colorectal cancer 210
Toll-like receptor 4 Asp299Gly and Thr399Ile polymorphisms in gastric cancer of intestinal and diffuse histotypes 209
Role of immunoglobulin G fragment C receptor polymorphism-mediated antibody-dependant cellular cytotoxicity in colorectal cancer treated with cetuximab therapy 209
Sex-Related Differences in Impact On Safety Of Pharmacogenetic Profile For Colon Cancer Patients Treated With FOLFOX-4 or XELOX Adjuvant Chemotherapy 209
TP53 mutation analysis in gastric cancer and clinical outcomes of patients with metastatic disease treated with Ramucirumab-Paclitaxel or standard chemotherapy 209
Hexokinase 208
Amplificazione enzimatica specifica di una regione di DNA strettamente associata alla Corea di Huntington 207
Early magnesium modifications as a surrogate marker of efficacy of cetuximab-based anticancer treatment in KRAS wild-type advanced colorectal cancer patients 207
Evaluation of Period 2 gene (PER-2) biologic profile in advanced colorectal cancer (ACC) patients treated with chronomodulated chemotherapy 207
Variations in the interleukin-1 receptor antagonist gene impact on survival of patients with advanced colorectal cancer. 205
Pharmacogenetic profiling for cetuximab plus irinotecan therapy in patients with refractory advanced colorectal cancer. 204
Let-7a microRNA levels in KRAS-mutated colorectal carcinomas determine survival differences in patients treated with anti-EGFR 204
NOD2/CARD15 polymorphisms impair innate immunity and increase susceptibility to gastric cancer in an Italian population 202
VEGF gene polymorphisms and susceptibility to colorectal cancer disease in italian population 201
The G/A Nucleotide Change at cDNA Position 2494 in the E-Cadherin Gene (CDH1): Analysis in Italian Patients 201
Host genetic variants in the IGF binding protein-3 impact on survival of patients with advanced gastric cancer treated with palliative chemotherapy 201
Retrospective exploratory analysis of VEGF polymorphisms in the prediction of benefit from first-line FOLFIRI plus bevacizumab in metastatic colorectal cancer 200
Prognostic Impact of TS, MTHFR and XRCC1 Genetic Variants in 113 Patients with Myelodysplastic Syndromes 198
The genotype of a new linked DNA marker, MP6d-9, is related to the clinicalcourse of cystic fibrosis. 197
Molecular analysis of G6PD variants in northern Italy: a study on the population from the Ferrara district. 197
Pharmacogenetic profiling and clinical outcome of patients with advanced gastric cancer treated with palliative chemotherapy. 196
High Let-7a MicroRNA Levels in KRAS-Mutated Colorectal Carcinomas May Rescue Anti-EGFR Therapy Effects in Patients with Chemotherapy-Refractory Metastatic Disease 196
Interleukin 1B gene (IL-1B) and interleukin 1 receptor antagonist gene (IL-1RN) polymorphisms in Helicobacter pylori-negative gastric cancer of intestinal and diffuse histotype. 196
Intratumoural FOXP3-positive regulatory T cells are associated with adverse prognosis in radically resected gastric cancer 194
Prospective validation of candidate SNPs of VEGF/VEGFR pathway in metastatic colorectal cancer patients treated with first-line FOLFIRI plus bevacizumab. 194
Dihydropyrimidine dehydrogenase pharmacogenetics for predicting fluoropyrimidine-related toxicity in the randomized, phase III adjuvant TOSCA trial in high-risk colon cancer patients. 194
Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFIRI chemotherapy 193
Emerging biomarkers in bladder cancer identified by network analysis of transcriptomic data 192
Role of KRAS let-7 LCS6 SNP in metastatic colorectal cancer patients 192
Structure of the 5' region of the human hexokinase type I (HKI) gene and identification of an additional testis-specific HKI mRNA 190
Predictors of benefit in colorectal cancer treated with cetuximab: are we getting "Lost in TranslationAL"? 189
PTEN EXPRESSION AND KRAS MUTATIONS AS PREDICTORS OF BENEFIT FROM CETUXIMAB PLUS IRINOTECAN (CETIRI) IN METASTATIC COLORECTAL CANCER (MCRC) PATIENTS (PTS) 188
Molecular predictors of efficacy to anti-EGFR agents in colorectal cancer patients 188
PHARMACOGENETIC PROFILING FOR TOXICITY OF OXALIPLATIN AND FLUOROPYRIMIDINES. FINAL REPORT FROM AN ANCILLARY PROTOCOL TO THE TOSCA TRIAL 187
Genetic activation of the MET pathway and prognosis of patients with high-risk, radically resected gastric cancer 187
High Concordance of KRAS Status Between Primary Colorectal Tumors and Related Metastatic Sites: Implications for Clinical Practice 186
BRAF mutations and EGFR Intron-1 L/L genotype are associated with resistance to cetuximab plus irinotecan treatment in KRAS wild-type metastatic colorectal cancer patients 185
K-RAS STATUS IN PRIMARY COLORECTAL TUMOURS CORRELATE WITH K-RAS STATUS IN RELATED METASTATIC SITES: IMPLICATIONS FOR TREATMENT WITH ANTI-EGFR ANTIBODIES IN CLINICAL SETTING 185
Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy 183
KRAS-mutated patients with liver-only metastatic colorectal cancer treated with Bevacizumab and chemotherapy. Functional analysis of TP53 mutations and outcomes 182
XRCC1 399GG GENOTYPE PREDICTS SIGNIFICANTLY LONGER OVERALL SURVIVAL AND LONG LASTING CR IN RESISTANT LYMPHOMA TREATED WITH BENDA-BEAM AND ASCT 182
Molecular analysis of G6PD variants in northern Italy: a study on the population from the Ferrara district 181
Combined analysis of E-cadherin gene (CDH1) promoter hypermethylation and E-cadherin protein expression in patients with gastric cancer: implications for treatment with demethylating drugs 179
Pharmacogenetic profiling for toxicity of oxaliplatin and fluoripyrimidines. An Ancillary protocol to the TOSCA trial 178
Association of BRAF mutations and EGFR Intron-1 L/L genotype with resistance to cetuximab plus irinotecan treatment in KRAS wild-type metastatic colorectal cancer patients 177
[Construction of an apparatus for pulsed field electrophoresis for the analysisof high molecular weight DNA] 176
Gender related differences in polymorphism and miRNA targeting CLOCK genes in metastatic colorectal cancer patients 176
Predictive and Prognostic Role of E-Cadherin Protein Expression in Patients with Advanced Gastric Carcinomas Treated with Palliative Chemotherapy 175
Glucose-6-phosphate dehydrogenase nucleotide 1311 polymorphism in central Italy(Marche Region). 175
Predictive and prognostic role of E-cadherin expression in patients with advanced gastric cancer treated with palliative chemotherapy. 174
ANALYSIS OF PTEN EXPRESSION AND KRAS MUTATIONS ON PRIMARIES (PRIM) AND METASTASES (METS) TO PREDICT BENEFIT FROM CETUXIMAB PLUS IRINOTECAN (CETIRI) IN METASTATIC COLORECTAL CANCER (MCRC) PATIENTS (PTS) 174
Prognostic role of thymidylate synthase polymorphisms in gastric cancer patientstreated with surgery and adjuvant chemotherapy. 174
Polymorphisms in genes involved in DNA repair and metabolism of xenobiotics in individual susceptibility to sporadic diffuse gastric cancer 173
Patients treated with FOLFOX-4 or XELOX chemotherapy with high-risk stage II and III colon cancer (TOSCA trial): a different impact of pharmacogenetic profile on toxicity in women and men 172
TS, MTHFR AND XRCC1 GENETIC VARIANTS AFFECT THE CLINICAL COURSE OF MDS PATIENTS IRRESPECTIVELY OF IPSS RISK 169
Structure of the human hexokinase type I gene. 169
Methylenetetrahydrofolate reductase 677C/T gene polymorphism, gastric cancer susceptibility and genomic DNA hypomethylation in an at-risk italian population 167
Prognostic Analysis of E-Cadherin Gene Promoter Hypermethylation in Patients with Surgically Resected, Node-Positive, Diffuse Gastric Cancer 165
MET tyrosine kinase receptor expression and amplification as prognostic biomarkers of survival in gastroesophageal adenocarcinoma 164
Clinical Relevance of ABCB1, ABCG2, and ABCC2 Gene Polymorphisms in Chronic Myeloid Leukemia Patients Treated With Nilotinib 164
Reply: KRAS status analysis and anti-EGFR therapies: is comprehensiveness a biologist's fancy or a clinical necessity? 164
Period 2 (PER-2) biologic profile in advanced colorectal cancer (ACC) patients (pts) 163
High concordance of BRAF status between primary colorectal tumours and related metastatic sites: implications for clinical practice 162
Linkage disequilibrium for DNA haplotypes near the cystic fibrosis locus in twosouth European populations 161
Molecular basis of the 2',3'-dideoxycytidine induced drug-resistance in human cells 160
Totale 20.669
Salva come PNG Salva come JPEG
Categoria #
all - tutte 98.872
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 98.872
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021666 0 0 0 0 0 0 0 0 0 224 349 93
2021/20221.753 116 188 210 223 82 69 76 95 107 84 81 422
2022/20231.954 286 78 22 201 252 413 7 103 360 70 96 66
2023/2024656 68 52 33 46 82 166 27 45 8 56 7 66
2024/20252.292 116 87 479 147 76 234 282 115 249 216 167 124
2025/20264.972 449 527 637 908 469 366 710 183 405 318 0 0
Totale 27.514